|Application ||WB, IHC-P, E|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||91869 Da|
|Antigen Region||428-456 aa|
|Other Names||Collagen alpha-1(IX) chain, COL9A1|
|Target/Specificity||This COL9A1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 428-456 amino acids from the Central region of human COL9A1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||COL9A1 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Structural component of hyaline cartilage and vitreous of the eye.|
|Cellular Location||Secreted, extracellular space, extracellular matrix|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
COL9A1 is one of the three alpha chains of type IX collagen, which is a minor (5-20%) collagen component of hyaline cartilage. Type IX collagen is usually found in tissues containing type II collagen, a fibrillar collagen. Studies in knockout mice have shown that synthesis of the alpha 1 chain is essential for assembly of type IX collagen molecules, a heterotrimeric molecule,and that lack of type IX collagen is associated with early onset osteoarthritis. Mutations in the COL9A1 gene are associated with osteoarthritis in humans, with multiple epiphyseal dysplasia, 6, a form of chondrodysplasia, and with Stickler syndrome, a disease characterized by ophthalmic, orofacial, articular, and auditory defects.
Fresquet,M., J. Biol. Chem. 282 (48), 34634-34643 (2007)
Liu,L.Y., Yi Chuan 29 (4), 427-432 (2007)
Van Camp,G., Am. J. Hum. Genet. 79 (3), 449-457 (2006)
Sivakumaran,T.A., J. Assoc. Res. Otolaryngol. 7 (2), 160-172 (2006)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.